MDxHealth S.A. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MDxHealth S.A. with three other
companies in this sector in Belgium:
Thrombogenics Nv
(2017
sales of 9.06 million Euro [US$10.59 million]
),
Ablynx N.V.
(55.53 million Euro [US$64.95 million]
of which 100%
was Nanobodies), and
argenx SE
(36.42 million Euro [US$42.59 million]
of which 55%
was Upfront Payments).
Sales Analysis.
MDxHealth S.A. reported sales of 35.56 million Euro (US$41.59 million)
for the
year ending
December of 2017.
This
represents
an
increase of 31.0%
versus 2016, when the company's sales were 27.15 million Euro.
Sales at MDxHealth S.A. have increased during each of the previous five years
(and since 2012, sales have increased a total of 673%).